<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939116</url>
  </required_header>
  <id_info>
    <org_study_id>ANG3070-CKD-201</org_study_id>
    <nct_id>NCT04939116</nct_id>
  </id_info>
  <brief_title>A Phase 2, Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Safety and Efficacy of ANG-3070 in Patients With Primary Glomerular Disease and Persistent Proteinuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angion Biomedica Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angion Biomedica Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major objective is to demonstrate the safety and efficacy of ANG-3070 in patients with&#xD;
      primary glomerular disease and persistent proteinuria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and efficacy of ANG-3070 in patients with primary glomerular disease&#xD;
      and persistent proteinuria while on the SOC, as measured by a reduction in the 24-hour&#xD;
      urinary protein excretion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 29, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in 24-hour urinary protein excretion at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Glomerular Disease</condition>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg of ANG-3070 will be taken once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg of ANG-3070 will be taken once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg of ANG-3070 will be taken twice a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules will be taken once or twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG-3070</intervention_name>
    <description>Orally administered tyrosine kinase inhibitor capsule</description>
    <arm_group_label>200 mg QD</arm_group_label>
    <arm_group_label>300 mg BID</arm_group_label>
    <arm_group_label>400 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Orally administered placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants aged 18 and older.&#xD;
&#xD;
          2. Diagnosis of a primary glomerular disease confirmed from a past renal biopsy.&#xD;
             Participants with genetic forms of FSGS may be enrolled without a renal biopsy if the&#xD;
             clinical picture is consistent with the genetic testing results.&#xD;
&#xD;
          3. Estimated glomerular filtration rate (eGFR) by Chronic Kidney Disease Epidemiology&#xD;
             Collaboration (CKD-EPI) ≥ 40 mL/min/1.73m2.&#xD;
&#xD;
          4. Urinary protein excretion ≥ 1 g/day on a 24-hour urine collection.&#xD;
&#xD;
          5. All participants must be on the SOC therapy, including the maximally&#xD;
             tolerated/recommended doses of an ACEi or ARB, but not both.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive Hepatitis B (HBV), Hepatitis C (HCV), or human immunodeficiency virus (HIV)&#xD;
             viral screening; historical or during screening.&#xD;
&#xD;
          2. Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) or total bilirubin&#xD;
             &gt; 2 x ULN.&#xD;
&#xD;
          3. Hemoglobin A1C &gt; 8.5%.&#xD;
&#xD;
          4. Known predisposition to bleeding and/or thrombosis&#xD;
&#xD;
          5. Type I diabetes mellitus.&#xD;
&#xD;
          6. Renal disease secondary to systemic disease including but not limited to: systemic&#xD;
             lupus erythematosus, anti-neutrophil cytoplasmic antibodies -associated diseases,&#xD;
             anti-glomerular basement disease, secondary forms of focal segmental&#xD;
             glomerulosclerosis, renal diseases associated with para-proteinemias, C3&#xD;
             glomerulopathy, and diabetic kidney disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Neylan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angion Biomedica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandy Dupee</last_name>
    <phone>857-378-4302</phone>
    <email>bdupee@angion.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glomerular Disease</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

